Napo therapeutics sponsoring pediatric gastroenterology conference: elite ped-gi congress in abu dhabi

Proof-of-concept studies of crofelemer in patients with short bowel syndrome (sbs) with intestinal failure or congenital diarrheal disorders planned for 2023 san francisco, ca / accesswire / may 1, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced that napo therapeutics, the corporation jaguar established in italy in 2021 that focuses on expanding access to the company's oral botanical drug crofelemer for orphan and rare diseases in europe, is a platinum sponsor of the 9th annual elite ped-gi congress, which takes place may 4-6, 2023 in abu dhabi in the united arab emirates. the annual elite ped-gi congress is designed to provide information about high level, clinically significant updates and comprehensive trends relevant to the practice of pediatric gastroenterological, nutrition and liver disorders.
JAGX Ratings Summary
JAGX Quant Ranking